A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability and pharmacokinetics of CR011-vcMMAE in
patients who have unresectable stage III or stage IV melanoma and have failed no more than 1
line of prior cytotoxic therapy. CR011-vcMMAE will be administered intravenously (IV) once
every 3 weeks at escalating doses until the maximum tolerated dose (MTD) is reached. Once the
MTD is defined, 18-32 patients will be enrolled to further evaluate the safety and efficacy
of CR011-vcMMAE at this dose level. Additional dosing schedules of CR011-vcMMAE will also be
explored.